Survival analysis revealed a median overall survival (mOS) of 37.2 months from diagnosis for patients with HER2-amplified CRC (n = 75), which was significantly lower than the mOS of 74.9 months for patients with CRC without HER2 amplification (P = 0.038). This evidence concerns the gene ERBB2 and colorectal carcinoma.